Major Programs
DCP's major programs span the cancer research continuum from initial agent and biomarker discovery at the laboratory to final Phase III clinical testing with people.
A consortium of seven Tumor Glycomics Laboratories and research partners, the Alliance is working to reveal the cancer-related dynamics of complex carbohydrates, and to develop new validated, clinical biomarkers for early cancer detection and risk assessment.
The Community Clinical Oncology Program (CCOP) is a coordinated, integrated clinical trials research network with more than 4,000 physicians who participate in NCI prevention, control, and treatment trials at more than 400 community-based hospitals, clinics, and private medical practices.
Six renowned cancer research centers lead multiple collaborative networks to assess the cancer prevention potential of new agents in this Consortia focused on Phase I and II clinical trials. In addition to designing and conducting trials and recruiting participants, the Consortia works to characterize the effects of potential agents on molecular targets and biological events associated with cancer development, and to correlate these effects with clinical endpoints. These efforts promote further scientific insights into the mechanisms of cancer prevention, and the development of novel potential markers as determinants of response.
The Early Detection Research Network (EDRN) brings together scientists from varied disciplines at more than 30 institutions to translate new molecular knowledge into practical clinical tests that identify cancer at the earliest stages. Government, academic and industrial leaders in molecular biology, genetics, clinical oncology, computer science, and public health collaborate.
The PREVENT Cancer Preclinical Drug Development Program is a unique partnership with to facilitate cancer preventative drug development and bring new cancer prevention agents and interventions to clinical trials.
Back to top
